288 related articles for article (PubMed ID: 36178508)
1. Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.
Kamińska K; Lenda T; Konieczny J; Lorenc-Koci E
Psychopharmacology (Berl); 2022 Nov; 239(11):3633-3656. PubMed ID: 36178508
[TBL] [Abstract][Full Text] [Related]
2. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E
Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201
[TBL] [Abstract][Full Text] [Related]
3. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
Lorenc-Koci E; Czarnecka A; Lenda T; Kamińska K; Konieczny J
Neurochem Int; 2013 Dec; 63(8):790-804. PubMed ID: 24090640
[TBL] [Abstract][Full Text] [Related]
4. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
5. Depressive-like neurochemical and behavioral markers of Parkinson's disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle.
Kamińska K; Lenda T; Konieczny J; Czarnecka A; Lorenc-Koci E
Pharmacol Rep; 2017 Oct; 69(5):985-994. PubMed ID: 28843848
[TBL] [Abstract][Full Text] [Related]
6. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
7. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
Chotibut T; Apple DM; Jefferis R; Salvatore MF
PLoS One; 2012; 7(12):e52322. PubMed ID: 23300642
[TBL] [Abstract][Full Text] [Related]
8. Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter.
Arai A; Tomiyama M; Kannari K; Kimura T; Suzuki C; Watanabe M; Kawarabayashi T; Shen H; Shoji M
Synapse; 2008 Aug; 62(8):632-5. PubMed ID: 18509855
[TBL] [Abstract][Full Text] [Related]
9. The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
Czarnecka A; Konieczny J; Lenda T; Lorenc-Koci E
Brain Res; 2015 Nov; 1625():218-37. PubMed ID: 26319690
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
[TBL] [Abstract][Full Text] [Related]
12. Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
Conti MM; Goldenberg AA; Kuberka A; Mohamed M; Eissa S; Lindenbach D; Bishop C
Pharmacol Biochem Behav; 2016 Mar; 142():64-71. PubMed ID: 26791104
[TBL] [Abstract][Full Text] [Related]
13. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.
Navailles S; Bioulac B; Gross C; De Deurwaerdère P
Neurobiol Dis; 2010 Apr; 38(1):136-43. PubMed ID: 20096781
[TBL] [Abstract][Full Text] [Related]
14. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Eskow Jaunarajs KL; George JA; Bishop C
Neuroscience; 2012 Aug; 218():243-56. PubMed ID: 22659568
[TBL] [Abstract][Full Text] [Related]
15. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
Chotibut T; Fields V; Salvatore MF
Mol Pharmacol; 2014 Dec; 86(6):675-85. PubMed ID: 25208966
[TBL] [Abstract][Full Text] [Related]
16. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Barnum CJ; Bhide N; Lindenbach D; Surrena MA; Goldenberg AA; Tignor S; Klioueva A; Walters H; Bishop C
Pharmacol Biochem Behav; 2012 Jan; 100(3):607-15. PubMed ID: 21978941
[TBL] [Abstract][Full Text] [Related]
17. L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo.
Miguelez C; Navailles S; Delaville C; Marquis L; Lagière M; Benazzouz A; Ugedo L; De Deurwaerdère P
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1297-309. PubMed ID: 27234917
[TBL] [Abstract][Full Text] [Related]
18. Piperine improves levodopa availability in the 6-OHDA-lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase.
Hu X; Yu L; Li Y; Li X; Zhao Y; Xiong L; Ai J; Chen Q; Wang X; Chen X; Ba Y; Wang Y; Wu X
CNS Neurosci Ther; 2024 Feb; 30(2):e14383. PubMed ID: 37528534
[TBL] [Abstract][Full Text] [Related]
19. High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease.
Navailles S; Benazzouz A; Bioulac B; Gross C; De Deurwaerdère P
J Neurosci; 2010 Feb; 30(6):2356-64. PubMed ID: 20147561
[TBL] [Abstract][Full Text] [Related]
20. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
